051

Size: px

Start display at page:

Download "051"

いちえいあいしま
7 years ago
Views:

1 June THE JAPANESE JOURNAL OF ANTIBIOTICS ( 83 ) NTT CHOP-R 5. DNA 1

2 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June NTT

3 June THE JAPANESE JOURNAL OF ANTIBIOTICS ( 85 ) Hb 9.7 g/dl, WBC 2200/µl cm, 46.8 kg (LevenII/VI) WBC 2,500/µl, Sg 39%, Mo 6%, Eo 3%, Ly 52% RBC /µl Hb 9.8 g/dl, Ht 28.4%, Plt /µl, Ret 1.1% NCC 48,000/µl, Mgk 32/µl, Reti 2.5%, Erythroid Seri 25.8%, Myeloid Seri 43.1%, BI 2.4%, Siderogram 0: 76%, I: 21%, II: 2%, III:1%, ring: 0% Karyotype 46 XY FAB (International Prognostic Scoring System: IPSS 0.5, Intermediate-1) WBC 1,000/µl, Seg 200/µl, CRP G-CSF Panipenem/Betamipron (PAPM/BP) CRP (WBC 2,100/µ l, Seg 189/µl) G-CSF PAPM/BP MRSA 3 (WBC 2,400/µl, Seg 456/µl) G-CSF Vancomycin (VCM) WBC 1,200/µ l, Seg 240/µ l MRSA Candida albicans G-CSF, VCM AMPH-B WBC 600/µ l, My 7%, Me 6%, St 15%, Sg 39%, Mo 5%, Eos 3%, Ba 2%, Ly 21%, Atypical Ly 2% RBC /µ l Hb 5.6g/dl, Ht 16.7%, Plt /µl, Ret 0.8%, NBT 44% 90% CRP 23 mg/dl β-d- ( 5 pg/ml) G-CSF 100 µ g/ Piperacillin (PIPC) 4 g/ Ceftazidime (CAZ) 2g/ CRP MRSA Gentamicin (GM), Teicoplanin (TEIC), Arbekacin (ABK), VCM, ST (TMP/ SMX) ABK 100 mg/ 4 1,500/µ l

4 298( 86 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June Figure Mirimostim (M-CSF) MRSA Meropenem (MEPM) 1.0 g/ VCM 0.5 g/ CRP 20 mg/dl (Figure) Pomeroy 64% CD11a, CD11b, CD11c, CD18 (CD35), CD15 NBT NADPH G- CSF 300/µ l

5 June G-CSF1,500/µ l MRSA THE JAPANESE JOURNAL OF ANTIBIOTICS ( 87 ) 5 β-d-

6 300( 88 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June (47,900/µ l) ,900/µ l, 79% 10.2 g/dl, 9.8 /µ l (Cr 1.81 mg/dl, CRP 9.91 mg/dl, UA 11.1 mg/dl) 384 PT 19 APTT /µ l, 1.5%, 92.2% (AML) FAB M5b (JALSG) AML201 (Idarubicin Ara-C) 1 Ara-C α-streptococcus β -D ( 5 pg/ml) pg/ml AMPH-B 0.4 mg/kg/ (Fig. 1) 5 4 Candida tropicalis AMPH-B 1.0 mg/kg/ 26 CT (Fig. 2) AMPH-B 1 mg/kg Micafungin (MCFG) 150 mg/ AMPH-B 30 mg/ MCFG 2 CRP β -D (Fig. 3), Candida tropicalis /µl 10 /µl mg/dl CRP mg/dl β-d- 1,090 pg/ml pg/ml 28 CRP (5.32 mg/dl), β-d- (1,920 pg/ml) MCFG CRP β-d-

7 June THE JAPANESE JOURNAL OF ANTIBIOTICS ( 89 ) Fig. 1. Fig. 2. CT Fig. 3. CT 2 3cm AMPH-B 0.5 mg/ Cr 3.1 mg/dl Fluconazole (FLCZ) β-d-cr AMPH-B 1 mg/ Itraconazole 200 mg/ β- D- 200 pg/ml CRP 4 mg/dl

8 302( 90 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June AMPH- B AMPH- B Itraconazole CT CT 5mm AMPH-B AMPH-B 0.4 mg/kg/ AMPH-B MCFG 150mg MCFG mg AMPH-B 150 mg Candida tropicalis G-CSF -γ M-CSF

9 June THE JAPANESE JOURNAL OF ANTIBIOTICS ( 91 ) ,500/m l, Hb 8.2 g/dl /ml (Myelodysplastic syndrome: MDS) /70 mmhg, 78/min 1,800/m l, /m l, Hb 9.1 g/dl, HCT 27%, /m l DIC (ALP 60 IU/l, ChE 2,965 mu/ml) (NCC) /m l Blast 5% MDS-RAEB (refractory anemia with excess of blasts: RARB), IPSS (International Prognostic Scoring System) intermediate-1 VEGA (Table 1) 2003 Table 1. VEGA Cytarabine 80 mg/m 2 civ 1 7 Etoposide 80 mg/m 2 div 1 5 Vindesine 2 mg/body iv G-CSF 200 m g/m 2 div 13 Fig. 1. CT

10 304( 92 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June JCS CT 17 CT (Fig. 1) 23 CT 27 (Fig. 1) (Fig. 2) Absidia Rhizopus Rhizomucor 1.6% 4 60% 5 AMPH-B Fig. 2.

11 June CT MDS-RAEB neutropenia THE JAPANESE JOURNAL OF ANTIBIOTICS ( 93 ) /4 AMPH-B b-d- AMPH-B1 mg/kg

12 306( 94 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 4 CHOP-R CHOP Rituximab cm 7,400/m l 16.1% (1,191/m L) IgG 632 mg/dl sil-2r 1,110 U/ml, CD % bcl2 ( ) t (14; 18)(q32; q21) CT B cell marker L26 (non-hodgkin s lymphoma: NHL) (duffuse mediumsized cell type, B cell type) stage IIIa, IPI (international prognostic index) low-intermediate risk CHOP Rituximab CHOP-R 7 39 CRP 9.3 mg/dl 2 CT (Fig. 1) 1,400/m l, 6% (84/m l) b-d- 103 pg/ml G-CSF 100 m g/ g - 5g/Sulbactam/Cefoperazone (SBT/CPZ) 5g/ Biapenem (BIPM) 1.2 g/ Clindamycin (CLDM) 1.2 g/ Fluconazole (FLCZ) 200 mg/ Itraconazole (ITCZ) 200 mg/(fig. 2) Itraconazole Micafungin (MCFG)150 mg/ AMPH-B b - D- 5 pg/ml AMPH-B Fig. 1. CT

13 June THE JAPANESE JOURNAL OF ANTIBIOTICS ( 95 ) Fig. 2. Fig. 3. AMPH-B CT Itraconazole Itraconazole 200 mg/ (Fig. 2) AMPH-B CT (Fig. 3) Rituximab B Rituximab CHOP Rituximab 7 CHOP-R 1,191/ml 84/m l CD % Rituximab CD20 bcl2 t (14; 18)(q32; q21) Rituximab CHOP Rituximab 8 8 CHOP Rituximab 4 2 CHOP Rituximab

14 308( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 5 DNA DNA DNA Febrile neutropenia, real-time PCR in vitro 6 (Human Herpes Virus 6: HHV-6) in vitro HHV-6 DNA DNA (Fig. 1) RNA Cy3 Cy5 DNA GenePix Genomic Profiler Fig. 1. DNA

15 June Fig. 2. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 97 ) Fig. 3. (Fig.2) (Fig. 3) real-time PCR U94 chemokine agonist U83 100% U83 U94 (Fig. 4) DNA HHV- 6BHHV-6B U11 U94 U100 (viral ligand for CD46) U83 (chemokine agonist vccl4)

16 310( 98 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June Fig. 4. U83 U94 Real-time PCR DNA DNA cross-hybridization in vitro HHV-6B DNA (CMV) (EBV) virushost interaction Celonex Inc (Fariborz Rahbar-Dehghan, Fengchun Ye, Lisa Penny) DNA RNA DNA

051

051 Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS